gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Risk reduction of colorectal cancer with long-term use of low-dose aspirin and nonsteroidal anti-inflammatory drugs

Meeting Abstract

Suche in Medline nach

  • corresponding author presenting/speaker Michael Hoffmeister - Deutsches Zentrum für Alternsforschung, Abteilung Epidemiologie, Heidelberg, Deutschland
  • Jenny Chang-Claude - Deutsches Krebsforschungszentrum, Arbeitsgruppe Genetische Epidemiologie, Heidelberg
  • Hermann Brenner - Deutsches Zentrum für Alternsforschung, Abteilung Epidemiologie, Heidelberg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO196

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk306.shtml

Veröffentlicht: 20. März 2006

© 2006 Hoffmeister et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: Long-term use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a reduced risk of colorectal cancer (CRC), but evidence regarding the role of age at initiation and required duration of use of different types of drugs is limited.

Methods: We assessed aspirin and non-aspirin NSAID use in 505 cases with histologically confirmed incident CRC and 575 control subjects in a population-based case-control study in Germany. Multiple logistic regression was used to estimate the impact of regular use of NSAIDs on CRC risk, with particular attention to type of medication, age at initiation and duration of use.

Results: Overall, the adjusted odds ratio (OR) of CRC for regular use of NSAIDs was 0.66 (95% confidence interval 0.49-0.90). Risk reduction was apparent already after 1-4 years of regular NSAID use (OR 0.62, 95% CI 0.40-0.97), and after at least 5 years if low-dose aspirin was used (OR 0.58, 95% CI 0.37-0.90). A strong protective effect of regular NSAID use was found even if medication was initiated after age 60 or 70 only.

Conclusions: In contrast to other studies on the risk of CRC, we found a protective effect of low-dose aspirin already after 5 years of daily use. Our findings suggest that a strong risk reduction may be achieved even with starting or continuing regular NSAID use above the age of 60 or 70. More studies are required to evaluate age-specific effects of long-term NSAID use and the effect of long-term use of low-dose aspirin every day and CRC risk.